Titan Biotech Limited has filed a regulatory notice with BSE Limited regarding newspaper advertisements pertaining to the loss of share certificates. The ISO 9001:2015 certified company submitted the filing on 06/04/2026 as part of its standard compliance procedures.

Regulatory Filing Details

The notice was submitted by Charanjit Singh, Compliance Officer (M.No A12726), to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai. The filing includes copies of newspaper advertisements published in both English and Hindi newspapers regarding lost share certificates.

Company Information and Compliance

Titan Biotech Limited maintains its office at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034. The company operates under CIN: L74999RJ1992PLC013387 and can be contacted at telephone numbers 011-27355742 and 011-71239900.

The regulatory filing demonstrates the company's adherence to standard corporate governance practices. When shareholders report lost or misplaced share certificates, listed companies are required to publish public notices in newspapers as part of the process for issuing duplicate certificates.

Publication and Website Hosting

As stated in the filing, the newspaper advertisements have been published in both English and Hindi newspapers to ensure broad accessibility. Additionally, the company has committed to hosting this information on its official website at www.titanbiotechltd.com , providing digital access to the notice.

This type of regulatory filing is routine for publicly listed companies and serves to protect both the company and shareholders' interests when dealing with lost share certificates. The dual-language publication ensures compliance with regulatory requirements while maximizing public awareness of the lost certificate notice.

Titan Biotech Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission demonstrates the company's adherence to mandatory reporting obligations for dematerialization processes.

Regulatory Compliance Filing

The compliance certificate was filed on April 4, 2026, addressing requirements under Regulation 74(5) of SEBI regulations for the quarter ended March 31, 2026. The document was signed by Charanjit Singh, serving as Compliance Officer with membership number A12726.

Registrar Confirmation Process

The compliance certificate was prepared based on confirmation received from Beetal Financial & Computer Services (P) Ltd, the company's SEBI-approved registrar and share transfer agent. Beetal Financial, holding SEBI registration number INR 000000262, provided its confirmation dated April 3, 2026.

The registrar's confirmation, signed by General Manager Punit Mittal, addressed several key compliance aspects:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depositories' names were substituted in the register of members as registered owners within the mandated 15-day period

Corporate Information

Titan Biotech Limited operates as an ISO 9001:2015 certified company with its registered office located at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034. The company maintains its corporate identification number as L74999RJ1992PLC013387.

Registrar and Transfer Agent Details

Beetal Financial & Computer Services (P) Ltd serves as the company's registrar and share transfer agent. The SEBI-approved category I registrar operates from Beetal House, 3rd Floor, 99 Madangir, Behind LSC, Near Dada Harsukhadas Mandir, New Delhi-110062.

This quarterly compliance filing represents part of the ongoing regulatory reporting requirements that publicly listed companies must fulfill to maintain transparency in their dematerialization processes and ensure proper handling of investor securities.